Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Novel transplant approaches in patients with AML

Justin Ching Ting Loke • 13 Dec 2021
ASH 2021
Acute Myeloid Leukemia Leukemia Azacitidine
AMADEUS

Justin Ching Ting Loke, BM BCh, PhD, University of Birmingham, Birmingham, UK, provides an overview of strategies to optimize allogeneic stem cell transplant in patients undergoing intensive and non-intensive treatment. Introduction of targeted therapies can reduce the intensity of transplant conditions, and minimal residual disease (MRD) monitoring can help improve patient outcomes. Additional strategies to improve transplantation outcomes include maintenance therapy, which has been investigated in the AMADEUS trial (NCT04173533), where maintenance azacitidine was assessed in patients with acute myeloid leukemia (AML). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Justin Ching Ting Loke

Predictors of outcomes in post-transplant patients with AML
2:27
Predictors of outcomes in post-transplant patients with AML
Justin Ching Ting Loke • 13 Dec 2021
Assessing COVID-19 infection rates in patients with AML and MPN
2:09
Assessing COVID-19 infection rates in patients with AML and MPN
Justin Ching Ting Loke • 13 Dec 2021

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals